If an expert committee votes to recommend it, the drug, molnupiravir, could be authorized within days for patients at high risk of severe illness.If an expert committee votes to recommend it, the drug, molnupiravir, could be authorized within days for patients at high risk of severe illness.Molnupiravir (Drug), Coronavirus (2019-nCoV), Merck & Company Inc, Food and Drug Administration, Coronavirus Omicron Variant, Vaccination and ImmunizationRead More
